TY - JOUR
T1 - Malignant tenosynovial giant cell tumor with CDKN2A/B genomic alteration
T2 - a histological, immunohistochemical, and molecular study
AU - Alexiev, Borislav Alexandrov
AU - Tumer, Yanki
AU - Yang, Guang-Yu
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Diffuse-type tenosynovial giant cell tumor (D-T TSGCT) is regarded as a benign but locally aggressive neoplasm with significant recurrent potential. We report a case of malignant D-T TSGCT with pleural metastases arising in the left knee in a 57-year-old man. The tumor demonstrated atypical features, including a solid infiltrative pattern with spindling of the tumor cells, nuclear pleomorphism with prominent nucleoli, and markedly increased mitotic activity (>20 mitoses/10 high-power fields). The immunoprofile demonstrated clusterin+, D2-40+, CD68+, p63+, MDM2+, and p16+ tumor. The next-generation sequencing–based assay demonstrated loss of the CDKN2A/B gene. Pleural metastases with identical histologic and immunohistochemical features were identified 2 years later after primary tumor resection. To the best of our knowledge, this is the first reported case of D-T TSGCT with CDKN2A/B genomic alteration, MDM2 expression, and p16 loss. Clinicians and pathologists should be aware of the morphologic variability and the metastatic propensity of this entity.
AB - Diffuse-type tenosynovial giant cell tumor (D-T TSGCT) is regarded as a benign but locally aggressive neoplasm with significant recurrent potential. We report a case of malignant D-T TSGCT with pleural metastases arising in the left knee in a 57-year-old man. The tumor demonstrated atypical features, including a solid infiltrative pattern with spindling of the tumor cells, nuclear pleomorphism with prominent nucleoli, and markedly increased mitotic activity (>20 mitoses/10 high-power fields). The immunoprofile demonstrated clusterin+, D2-40+, CD68+, p63+, MDM2+, and p16+ tumor. The next-generation sequencing–based assay demonstrated loss of the CDKN2A/B gene. Pleural metastases with identical histologic and immunohistochemical features were identified 2 years later after primary tumor resection. To the best of our knowledge, this is the first reported case of D-T TSGCT with CDKN2A/B genomic alteration, MDM2 expression, and p16 loss. Clinicians and pathologists should be aware of the morphologic variability and the metastatic propensity of this entity.
KW - CDKN2A/B loss
KW - Giant cell tumor
KW - Metastases
UR - http://www.scopus.com/inward/record.url?scp=85018653172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018653172&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2016.12.003
DO - 10.1016/j.humpath.2016.12.003
M3 - Article
C2 - 27989786
AN - SCOPUS:85018653172
SN - 0046-8177
VL - 63
SP - 144
EP - 148
JO - Human Pathology
JF - Human Pathology
ER -